ArticleCancers2025
Characterizing Overall Survival of Patients with Acute Myeloid Leukemia: A Competing Risk Analysis of SEER Data Covering 46 Years.
Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hierarchical lineage tracing reveals diverse pathways of cytarabine resistance.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
methodsWe analyzed trends in overall survival after acute myeloid leukemia (AML) using US registry data covering the years 1975 to 2021. Our study utilized unique patient data from the Surveillance, Epidemiology, and End Results Program (SEER), with 37,615 adult patients included. We employed Kaplan-Meier estimates and competing risk analyses to assess overall survival and risks of AML-related death and death from other causes.
resultsOur findings indicate a clear and continuous trend of improved survival in AML patients, attributed to decreased AML-related mortality. Patients aged 60 or younger showed continuous improvement over the entire period, while those aged 61 or older demonstrated improvement starting in the early 2000s. Only patients receiving chemotherapy treatment benefited from ongoing research. No sex-specific differences were found. Subgroup analyses revealed age-dependent differences in survival improvement. The delayed onset of improvement in older patients may be due to the availability of hypomethylating agents and increased access to hematological stem cell transplantation.
conclusionOur analysis showed, on a high level of abstraction, how ongoing research and availability of new treatment options improved survival for AML patients. Furthermore, subgroup analyses revealed age-dependent differences in this respect. While the data did not allow us to conduct in-depth analyses of treatment regimens, we hypothesized that the later onset of a pattern of improvement in older patients was due to the availability of hypomethylating substances and increased availability of hematological stem cells transplantation for elderly patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.